Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) and DarioHealth (NASDAQ:DRIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.
Profitability
This table compares Spectral Diagnostics and DarioHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spectral Diagnostics | -1,378.12% | N/A | -627.93% |
| DarioHealth | -192.23% | -60.52% | -37.08% |
Insider & Institutional Ownership
33.4% of DarioHealth shares are held by institutional investors. 1.5% of Spectral Diagnostics shares are held by insiders. Comparatively, 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Analyst Recommendations
This is a summary of current ratings and recommmendations for Spectral Diagnostics and DarioHealth, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spectral Diagnostics | 0 | 0 | 0 | 0 | 0.00 |
| DarioHealth | 1 | 1 | 1 | 0 | 2.00 |
DarioHealth has a consensus target price of $10.50, suggesting a potential upside of 54.98%. Given DarioHealth’s stronger consensus rating and higher probable upside, analysts plainly believe DarioHealth is more favorable than Spectral Diagnostics.
Valuation & Earnings
This table compares Spectral Diagnostics and DarioHealth”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spectral Diagnostics | $1.75 million | 158.93 | -$34.13 million | ($0.10) | -9.48 |
| DarioHealth | $22.36 million | 2.21 | -$41.71 million | ($8.88) | -0.76 |
Spectral Diagnostics has higher earnings, but lower revenue than DarioHealth. Spectral Diagnostics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
Summary
DarioHealth beats Spectral Diagnostics on 10 of the 14 factors compared between the two stocks.
About Spectral Diagnostics
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
About DarioHealth
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
